Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is launching the new VisioNize® Laboratory News
The journey and merging of sperm and egg cells is
This year, the Hamburg based life sciences company
Cipla Limited (BSE: 5
Since it’s an ingredient in so many foods, you h
In a world constantly in motion, Microbioz India r
On Monday, Nacto Pharma reported that over two-fold increase in consolidated profit after the tax at Rs.181.6 crore for the second quarter ended September 30,2018. The company also posted a consolidated profit after the tax of Rs 84.4 crore in the same quarter last fiscal, Natco Pharma said in a regulatory filing.
The total revenue under the period stood at Rs. 583.5 crore. It was at Rs 432.2 crore in the year ago quarter. The company said in their board of directors meeting on Monday had agreed about the buyback of the completely paid-up equity shares of face value of Rs.2 each with a price which not exceeding Rs 1,000 per share for an aggregate amount of Rs 2,50 crores from the open market through the stock exchange mechanism.
The company said in their board of directors meeting on Monday had agreed about the buyback of the completely paid-up equity shares of face value of Rs.2 each with a price which not exceeding Rs 1,000 per share for an aggregate amount of Rs 2,50 crores from the open market through the stock exchange mechanism.
The maximum buyback size represents 8.10 per cent and 8.22 per cent of the aggregate of the total paid up equity capital and free reserves, respectively, of the company, it added.
